We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. VONJO^TM is a trademark of CTI BioPharma Corp.
View Top Employees from CTI BioPharmaWebsite | http://www.ctibiopharma.com |
Ticker | CTIC |
Revenue | $26 million |
Employees | 172 (172 on RocketReach) |
Founded | 1992 |
Address | 3101 Western Ave. # 600, Seattle, Washington 98121, US |
Phone | (206) 282-7100 |
Fax | (206) 284-6206 |
Industry | Biotechnology, Drug Manufacturing & Research, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Therapeutics |
Web Rank | 5 Million |
Keywords | Cti Biopharma, Cti Biopharma News, Ctic Investor Relations, Aza Chop, Cell Therapeutics Avviso Assemblea 2011 |
Competitors | Mersana Therapeutics, Mirati Therapeutics Inc, Ocugen, Spectrum Pharmaceuticals, Inc., Verastem Oncology |
SIC | SIC Code 37 Companies, SIC Code 87 Companies, SIC Code 28 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 32 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 33 Companies, NAICS Code 541711 Companies, NAICS Code 325 Companies |
Looking for a particular CTI BioPharma employee's phone or email?
The CTI BioPharma annual revenue was $26 million in 2024.
John Volpone is the Executive Vice President and Chief of Staff of CTI BioPharma.
172 people are employed at CTI BioPharma.
CTI BioPharma is based in Seattle, Washington.
The NAICS codes for CTI BioPharma are [541, 54, 32, 54171, 5417, 33, 541711, 325].
The SIC codes for CTI BioPharma are [37, 87, 28, 873].